Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced ...

Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement ...

In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% ...

Detailed price information for Chemomab Therapeutics Ltd ADR (CMMB-Q) from The Globe and Mail including charting and trades.

This framework enables quantitative predictions about how cellular systems convert frequency-encoded signals into precise ...

Received FDA Fast Track designation for stenoparib in advanced ovarian cancerReported landmark median overall survival now exceeding 25 ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Cavefish exhibit resilience to chronic sleep loss and tolerate elevated DNA damage and reduced DNA repair responses without compromising healthspan or longevity.

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Explore Abivax’s RNA-based drug innovations and clinical progress in the healthcare sector, aligning with global trends ...

GLAC Biotech, a leading innovator in probiotics and postbiotics research, proudly announces another milestone on the ...